Theriva Biologics, Inc. (TOVX)

ASE – Real vaqt narxi. Valyuta: USD

0.32

-0.02 (-5.60%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.33

+0.01 (2.52%)

Bozordan keyin: May 12, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Theriva Biologics, Inc. (TOVX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Theriva Biologics, Inc. (TOVX)

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Why Is Theriva Stock Gaining Monday?

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Videolar

No Data

Press-relizlar

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action

Search stocks

Theriva Biologics, Inc. (TOVX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Theriva Biologics, Inc. (TOVX)

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Why Is Theriva Stock Gaining Monday?

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Videolar

No Data

Press-relizlar

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action